These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 26181015)

  • 1. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Wilson LE; Pollack CE; Greiner MA; Dinan MA
    Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Chu QD; Zhou M; Medeiros KL; Peddi P; Wu XC
    Anticancer Res; 2017 Oct; 37(10):5585-5594. PubMed ID: 28982874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    Orucevic A; Heidel RE; Bell JL
    Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
    Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
    J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
    Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
    J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
    Enewold L; Geiger AM; Zujewski J; Harlan LC
    Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining Treatment Decisions in Older Patients With Breast Cancer.
    Flaum L; Gradishar WJ
    JAMA Oncol; 2015 May; 1(2):166-7. PubMed ID: 26181016
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation in positron emission tomography use after colon cancer resection.
    Bailey CE; Hu CY; You YN; Kaur H; Ernst RD; Chang GJ
    J Oncol Pract; 2015 May; 11(3):e363-72. PubMed ID: 25852143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
    Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
    Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
    Dinan MA; Wilson LE; Reed SD
    J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.
    Hershman DL; Buono D; McBride RB; Tsai WY; Joseph KA; Grann VR; Jacobson JS
    J Natl Cancer Inst; 2008 Feb; 100(3):199-206. PubMed ID: 18230795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
    Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
    JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.